To benchmark the efficacy of alnustone against existing drugs, we compared the therapeutic effects of alnustone with Farnesoid X‐receptor (FXR) agonist obeticholic acid (OCA), a currently used classical drug for clinical treatment of MASLD and is being tested in phase III clinical trials in patients with MASH.[29] OCA was administered with the same dose of alnustone in MCD‐induced MASH mice. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.